公开(公告)号：US09333255B2

公开(公告)日：2016-05-10

申请号：US14043402

申请日：2013-10-01

Applicant: Novo Norkisk A/S ,  Innate Pharma S.A.S.

Inventor： Peter Andreas Nicolai Reumert Wagtmann ,  Francois Romagne ,  Joakim Glamann

IPC: C07K16/28 ,  C07K16/08 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/08 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.

Abstract translation: 描述了使用阻断抑制性NK细胞受体的化合物治疗病毒性疾病的方法，从而降低其在杀死感染的靶细胞中NK细胞的细胞毒性的抑制。 在一个实施方案中，所述化合物是结合例如人KIR2DL1，KIR2DL2和KIR2DL3受体中的一种或多种的抗体。 在另一个实施方案中，所述方法还包括施用结合感染病毒的细胞上表达的抗原的治疗性抗体或融合蛋白。

公开(公告)号：US20160114056A1

公开(公告)日：2016-04-28

申请号：US14898693

申请日：2014-06-20

Applicant: Innate Pharma

Inventor： Delphine Bregeon

IPC: A61K47/48 ,  A61K38/05 ,  C07K16/00 ,  C12P21/00

CPC classification number: A61K47/48415 ,  A61K38/05 ,  A61K47/6803 ,  A61K47/6811 ,  C07K16/00 ,  C07K2317/14 ,  C12P21/005

Abstract: One embodiment relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Abstract translation: 一个实施方案涉及用于免疫球蛋白酶促功能化的方法，特别是与药物。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。

公开(公告)号：US20160022833A1

公开(公告)日：2016-01-28

申请号：US14775647

申请日：2014-03-14

Applicant: INNATE PHARMA

Inventor： Delphine Bregeon

IPC: A61K47/48 ,  C07K16/00

CPC classification number: C07K16/00 ,  A61K47/68 ,  A61K47/6803 ,  C07K2317/41

Abstract: Some embodiments described herein relate to solid-support based processess for the functionalization of immunoglobulins through the use of transglutaminase. Also provided are solid support compositions with bound antibody. The methods can be used, for example, in manufacturing processes or in drug screening.

Abstract translation: 本文描述的一些实施方案涉及通过使用转谷氨酰胺酶来实现免疫球蛋白功能化的基于固相支持的方法。 还提供了具有结合抗体的固体支持物组合物。 该方法可用于例如制造过程或药物筛选。

公开(公告)号：US20150344576A1

公开(公告)日：2015-12-03

申请号：US14829170

申请日：2015-08-18

Applicant: Novo Nordisk A/S - Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许哺乳动物受试者中NK细胞细胞毒性增强的抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US20150283234A1

公开(公告)日：2015-10-08

申请号：US14437029

申请日：2013-10-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  INNATE PHARMA

Inventor： Robert F. Graziano ,  Ashok K. Gupta ,  Su Young Kim ,  Jon Wigginton ,  Pascale Andre

IPC: A61K39/395 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/565 ,  C07K2317/92

Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

Abstract translation: 提供了使用抗-KIR抗体与抗CTLA-4抗体组合的临床治疗癌症（例如实体瘤或血液恶性肿瘤）的方法。

公开(公告)号：US20150191547A1

公开(公告)日：2015-07-09

申请号：US14659045

申请日：2015-03-16

Applicant: Novo Nordisk A/S - Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C07K16/42

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

公开(公告)号：US20150165064A1

公开(公告)日：2015-06-18

申请号：US14582040

申请日：2014-12-23

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Laurent Gauthier ,  François Romagne ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/48 ,  A61K31/5517

CPC classification number: A61K47/48569 ,  A61K31/5517 ,  A61K47/48384 ,  A61K47/48715 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/40

Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Abstract translation: 本申请涉及免疫球蛋白的酶官能化方法，特别是与药物的方法。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。

公开(公告)号：US20130287770A1

公开(公告)日：2013-10-31

申请号：US13936486

申请日：2013-07-08

Applicant: INNATE PHARMA S.A.S. ,  NOVO-NORDISK A/S - NOVO ALLE

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Loius Spee ,  Milchael Wilken

IPC: C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US20250092130A1

公开(公告)日：2025-03-20

申请号：US18823932

申请日：2024-09-04

Applicant: INNATE PHARMA

Inventor： CÉCILE BONNAFOUS ,  HÉLÈNE SICARD ,  RENAUD BUFFET

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30 ,  G01N33/574

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US20240368281A1

公开(公告)日：2024-11-07

申请号：US18772517

申请日：2024-07-15

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.